Conveners
Postersession
- Judith Reindl
Minibeam therapy faces challenges in preserving deep-seated normal tissue due to the lateral spreading of minibeams caused by small-angle scattering. Unlike proton minibeams, helium or carbon minibeams experience less spreading, potentially reducing side effects. Studies with proton beams indicate that reaching full therapeutic potential of minibeam therapy requires high beam brightness....
The primary aim of radical radiotherapy is to effectively treat tumors while minimizing damage to normal tissues. Hadron therapy, utilizing heavy particles such as protons, alpha particles, and carbon ions, provides a unique advantage over conventional photon therapy, which can be increased by the use of spatial fractionation. The focus of this research project is to further enhance the effect...
Proton minibeam therapy (pMBT) using sub-millimeter beams spaced a few millimeters apart has demonstrated the ability to reduce side effects in normal tissues and possible increase of the therapeutic ratio. Preclinical studies also indicate that FLASH irradiation, delivering ultra-high dose rates (>40 Gy/s), minimizes tissue toxicity while maintaining effective tumor control. However,...
Proton minibeam radiation therapy (pMBT) and FLASH radiotherapy (FLASH-RT) have attracted the interest of scientists due to the better sparing of healthy tissue compared to conventional modalities. Combining these methods may lead to further reduction of the induced side effects. In this proof-of-principle study, the feasibility of designing a ridge filter (RF) for the FLASH application of...
Automated detection and tracking of living cells in microscopy recordings by deep learning algorithms may considerably speed up and facilitate evaluation compared to manual post-processing. However, the performance of such algorithms on individual sets of cell data and their generalizability differ significantly. One approach is to use a deep learning object detection model, which identifies...
In collaboration with the Helmholtz Zentrum Berlin (HZB) a new pMBT facility, called MINIBEE, is currently under construction. The facility will include a small animal radiation research platform (SARRP) for positioning small animals or in vitro samples, X-ray irradiation, onboard CT-imaging, and treatment planning. Additionally, there will be a microscope that enables imaging of samples...
Healthy tissue toxicity limitations of neon beams may be overcome by combining such ions with the remarkable normal tissue sparing that spatially fractionated radiotherapies provide. The present study explores the biochemical effects involved at a single-cell level in neon minibeam radiation therapy (NeMBRT) using synchrotron-based Fourier transform infrared microspectroscopy (SR-FTIRM). This...
Radiotherapy is one of three methods used to fight against cancer along with surgery and chemotherapy, and has currently attracted a lot of scientific interest particularly due to novel techniques, like Proton Minibeam Radiotherapy (pMBT) and FLASH therapy. The latter can deliver an ultra-high dose rate of radiation to the target (>40 Gy/s). From a biological aspect, the main target of...
LhARA (Laser-hybrid Accelerator for Radiobiological Applications) is conceived as a novel, uniquely flexible facility dedicated to the study of the biological response to ionising radiation. The design for LhARA offers versatility, allowing for the production of spatially fractionated radiation therapy (SFRT) at the in-vitro and in-vivo end stations.
Background
SFRT aims to minimise...
Introduction
Microbeam Radiotherapy (MRT) and Minibeam Radiotheraoy (MBRT) have proven to not only increase normal tissue tolerance but also the ability to combat tumors more effectively. The latter aspect is the focus of our research, where we are interested in the tumor control probability of MRT and MBRT compared to conventional uniform doses.
Methods
A549 cells were injected...
Background and Objectives: The 18 MeV medical cyclotron at Bern University Hospital (Inselspital) is designed for routine radiopharmaceutical production. It is equipped with a Beam Transfer Line (BTL), accessible in a separate bunker, for research in medical applications of particle physics. In an effort to make pre-clinical proton therapy studies more accessible to research groups, the BTL...
Preclinical and clinical studies have shown that radiation delivery at ultra-high dose rate (UHDR, > 40 Gy/s) and sufficiently high total dose elicits the FLASH effect that maintains anti-tumor efficacy and spares normal tissue as compared with conventional dose rate (0.05 Gy/s), used in RT clinical practice. The 22 MeV electron PITZ beam delivers radiation at both UHDR up to unique 10^14 Gy/s...
After 25 years of successful research in the nuclear and radiation physics and biology domain, the KVI-CART research center in Groningen has been re-focussed and re-established as the open access UMCG PARticle Therapy Research Center (PARTREC). Using the superconducting cyclotron AGOR and being embedded within the University Medical Center Groningen, it operates in synergy with the clinical...
roton minibeam radiation therapy (pMBRT) is a novel therapeutic approach offering great promise for the treatment of radioresistant tumors based on the spatial fractionation of the dose. pMBRT applies a high dose modulation consisting of high doses (peaks) deposited in the paths of millimetric planar beams and low doses (valleys) in the rest of the tissue. This distinct dose delivery leads to...
The Centre for Accelerator Science (CAS) of the Australian Nuclear Science and Technology Organisation (ANSTO) is a national state-of-art facility for applied accelerator science, equipped with 10 MV Van de Graaff ANTARES [1] accelerator to accelerate mono-energetic ions, such as proton up to 10 MeV (ideally 20 MeV), light and heavy ions up to 120 MeV.
The Heavy Ion Nuclear Microprobes...
CNAO is one of the four centres in Europe, and six worldwide, offering treatment of tumours with both protons and carbon ions. Since its start in September 2011 almost 4500 patients have been treated. In addition to clinical activity, CNAO performs research as an institutional mission. In this framework a room dedicated to experimental activities is available and open also to external...
Contact: Elisabeth Bodenstein - Beamline Scientist elisabeth.bodenstein@oncoray.de
Jörg Pawelke - Core Facility Manager joerg.pawelke@oncoray.de
An innovative proton facility is at the heart of the OncoRay research building. While cancer patients are being treated in the clinical part, scientists can concurrently conduct research in the experimental area of the University Proton Therapy...
The Proton Therapy Research Centre (PTRC) at the TRIUMF particle accelerator center in Vancouver, British Columbia, Canada, conducts pre-clinical and dosimetry research with the proton therapy beam line that clinically treated ocular cancer between 1995 and 2018. Extracted proton energies between 116 MeV and 70 MeV are available, with most of the work being conducted at the former treatment...
An R&D platform for electron FLASH radiation therapy and radiation biology is being prepared at the Photo Injector Test facility at DESY in Zeuthen (FLASHlab@PITZ) [1]. This platform is based on the unique beam parameters available at PITZ: ps scale electron bunches of 6 to 22 MeV with up to 5 nC bunch charge at MHz bunch repetition rate in bunch trains of up to 1 ms in length repeating at 1...
Particle radiation research is crucial for advancing our understanding of radiobiology and its applications in medicine. As an evolving field, it focuses on studying the interactions of charged particles, such as protons and heavy ions, with biological tissues. This research provides insights into the effects of particle radiation on cells, DNA, and tissues, enabling us to develop safer and...
Compared to classic proton therapy, proton minibeam radiation therapy (pMBT) further spares normal tissue. To fully study this potential with small animal experiments focused minibeams with a σ of 50 μm , a beam current of 1 nA and approx. 4 cm proton range (water) is needed. The MiniBEE located at the Helmholtz-Zentrum Berlin, is designed to fullfill all requirements of researchers for...
A research version of the RayStation treatment planning system dedicated to particle therapy related explorations has been developed. It provides, for research purposes (ie. non-clinical use), the following features not available in clinical releases of the RayStation system:
• Scorers: Trackends, LETd, LETt, Qefft,Qeffd, dose components, 10+ RBE models (McNamara, RMF, DDK…), dose rate,...
The goal of the ERC-funded project SIRMIO (Small animal proton irradiator for research in molecular image-guided radiation-oncology) has been to realize an innovative portable system to enable precision image-guided small animal proton irradiation at existing beamlines of clinical proton therapy facilities. The modular SIRMIO system combines a dedicated beamline consisting of passive and...
Department of Physics at University of Oslo operates a MC-35 cyclotron (Scanditronix AB in Uppsala, Sweden), which includes a cell irradiation set-up with an adjacent cell laboratory.
The cyclotron accelerates 1H+(8 − 35 MeV), 2H+ (4 − 18 MeV), 3He2+ (6 − 47 MeV), and 4He2+ (8 − 35 MeV). For cell irradiation, only protons of 15 MeV have so far been used. A 50 µm W foil scatters the beam to...
Contact: experimente@mit-marburg.de | matthias.witt@mit-marburg.de | matthias.witt@lse.thm.de
Physical beam properties at MIT
The Marburg Ion Beam Therapy Center (MIT) is one of four European Hadron Therapy Centers that offer raster scanning for both proton and carbon ions. The synchrotron-based accelerator provides protons in the energy range of 48.08 MeV to 221.07 MeV and carbon ions from...
The University of Washington (UW) Medical Center operates a Scanditronix MC50 multi-particle, variable energy cyclotron for fast neutron therapy patient care, radioisotope production, radiation-effects testing of electronic devices, and translational in vitro and in vivo research. The cyclotron is located within the UW Radiation Oncology Department and has four beamlines. The first beamline is...
